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Abstract
Cancer initiation and progression involve microRNAs that can function like tumor suppressors and oncogenes. The
functional significance of most miRNAs is currently unknown. To determine systematically which microRNAs are essential for
glioma growth, we screened a precursor microRNA library in three human glioblastoma and one astroglial cell line model
systems. The most prominent and consistent cell proliferation–reducing hits were validated in secondary screening with an
additional apoptosis endpoint. The functional screening data were integrated in the miRNA expression data to find
underexpressed true functional tumor suppressor miRNAs. In addition, we used miRNA-target gene predictions and
combined siRNA functional screening data to find the most probable miRNA-target gene pairs with a similar functional
effect on proliferation. Nine novel functional miRNAs (hsa-miR-129, -136, -145, -155, -181b, -342-5p, -342-3p, -376a/b) in
GBM cell lines were validated for their importance in glioma cell growth, and similar effects for six target genes (ROCK1,
RHOA, MET, CSF1R, EIF2AK1, FGF7) of these miRNAs were shown functionally. The clinical significance of the functional hits
was validated in miRNA expression data from the TCGA glioblastoma multiforme (GBM) tumor cohort. Five tumor
suppressor miRNAs (hsa-miR-136, -145, -342, -129, -376a) showed significant underexpression in clinical GBM tumor samples
from the TCGA GBM cohort further supporting the role of these miRNAs in vivo. Most importantly, higher hsa-miR-145
expression in GBM tumors yielded significantly better survival (p,0.005) in a subset of patients thus validating it as
a genuine tumor suppressor miRNA. This systematic functional profiling provides important new knowledge about
functionally relevant miRNAs in GBM biology and may offer new targets for treating glioma.
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Introduction
MicroRNAs (miRNAs) are about 22–25 nt long, noncoding
RNAs originally discovered in Caenorhabditis elegans [1]. MiRNA is
produced from primary transcripts via release of 60–70 nt stem-
loop intermediates known as pre-miRNA, which are then cleaved
by Dicer to produce double-stranded RNA duplexes consisting of
mature miRNAs and their antisense strand. Cancer initiation and
progression can involve miRNAs as reviewed by [2,3]. MiRNAs
can function as tumor suppressors and oncogenes or ‘‘oncomirs’’
[4]. Functional studies have also revealed that miRNAs play an
important role in regulating various cellular processes, including
proliferation, stem cell renewal, and differentiation [5].
Glioblastoma multiforme (GBM) is the most common and
aggressive primary brain tumor, with approximately 10,000 new
cases per year in the US [6]. Patients with newly diagnosed GBM
have a median survival period of approximately one year.
Similarly to other cancers, a characteristic microRNA expression
pattern is seen in glioblastomas. For instance, several brain-
enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-
181c, are mainly down-regulated in glioblastomas [7], whereas
miR-221 and miR-21 are strongly up-regulated in GBM and
grade II–IV astrocytic tumors [8].
Each deregulated miRNA can target hundreds or even
thousands of genes by transcriptional silencing at the mRNA level
or translational inhibition at the protein level. For a few miRNAs,
their specific individual target genes have been proven with 3-
untranslated region (39UTR) assays, and functions have been
analyzed by down-regulating or overexpressing the miRNAs.
However, no genome-wide studies exist with a systematic analysis
of miRNA functions in gliomas. In this study, we used miRNA
precursor libraries systematically in overexpression screenings to
identify miRNAs that reduce proliferation or increase apoptosis in
glioma cell lines. In cancer, the loss of tumor-suppressive miRNAs
enhances the expression of target oncogenes. Since each miRNA
can target thousands of genes, we used target predictions and
combined small interfering RNA (siRNA) functional screening
data to find the most probable miRNA-target gene pairs that have
similar functional effects. Six genes were found and validated at
the miRNA and gene expression level in clinical GBM samples.
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Materials and Methods
Cell Culture and Reagents
Human glioblastoma cell lines A172 and U87MG were
obtained from ECACC (Salisbury, UK) in 2003, LN405 from
the DSMZ (Braunschweig, Germany) in 2003, and astroglia
SVGp12 from American Type Culture Collection (Manassas, VA,
USA) in 2006. Cells were cultured in medium conditions
recommended by the providers for less than 4 months before
being used in these experiments. All siRNAs were purchased from
Qiagen (Qiagen GmbH, Hilden, Germany). Additional control
siRNAs were AllStars Hs Cell Death Control siRNA (Qiagen) and
Negative Control siRNA (siNEG, Qiagen). The siRNAs were used
at a final concentration of 15 nM each.
Total cellular RNA including small RNAs was isolated for
miRNA expression profiling using the mirVana miRNA Isolation
Kit (Ambion Inc., Austin, TX, USA). Total cellular RNA for gene
expression profiling was extracted using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA) followed by purification of the RNA
using Qiagen’s RNeasy columns (Valencia, CA, USA) according
to the manufacturer’s instructions.
MicroRNA Functional Screening and Data Analysis
The A172, LN405, U87MG, and SVGp12 cells were
transfected with 20 nM human Pre-miR miRNA Precursor library
v2 (Ambion Inc., 319 molecules). Negative controls included in the
screenings were pre-miR miRNA precursor negative controls #1
and #2 (Ambion) and a scrambled control mirCURY knockdown
probe (Exiqon A/S, Vedbaek, Denmark). For cell viability
screening, miRNAs were printed (Hamilton Bonaduz AG,
Bonaduz, Switzerland) in 384-well plates (Greiner Bio-One,
Stonehouse, Germany) to reach the final assay concentration of
20 nM. SilentFect transfection agent (Bio-Rad Laboratories,
Hercules, CA, USA) was diluted in OptiMEM (Gibco Invitrogen,
Paisley, CA, USA), incubated for 10 min at room temperature,
and aliquoted to wells using Multidrop 384 Microplate Dispenser
(Thermo Labsystems, Thermo Electron Corporation, Waltham,
MA, USA). Plates were then incubated for 1 h at room
temperature. The predetermined optimal number of cells
(1,000–1,500 cells per well) was then added to the plates, and
further incubated for 72 h at 37uC with 5% CO2. Cell viability
was measured with the CellTiterBlue assay (Promega Corp,
Madison, WI, USA). The EnVision Multilabel Plate Reader
(PerkinElmer Inc., Waltham, MA, USA) was used for signal
quantification. The miRNA screening data were normalized plate-
wise for row and column effects, and the results from the replicate
screenings were combined for the analyses.
Secondary Validation Assays for miRNA Functional
Screening
Transfections were performed as described in the microRNA
functional screening and data analysis section but in 6-well and
384-well formats. Cell viability was measured with the CellTiter-
Glo assay, and induction of caspase-3 and -7 activities was
detected with the homogenous Caspase-Glo 3/7 Assay (Promega
Corp, Madison, WI, USA). The EnVision Multilabel Plate Reader
(PerkinElmer) was used for signal quantification. The miRNA
screening data was normalized plate-wise for row and column
effects, and the results from the replicate screenings were
combined for the analyses.
Live Cell Time-lapse Microscopy
Cell growth and confluence were monitored by taking time-
lapse phase contrast images with an IncuCytePlus microscope
(Essen Instruments Inc, Ann Arbor, MI, USA) once per hour of
live cells grown for 4 days in a CO2 incubator.
Cell Cycle Assays
The cell cycle was analyzed using the Click-it Edu Alexa
647 nm fluor HCS assay kit (Invitrogen) according to the
Figure 1. Functional screening for miRNAs affecting glioma cell
line proliferation after overexpression of precursor miRNAs. A)
Hierarchical clustering of repeating hits from the miRNA pre-miR
functional proliferation primary screening using the Euclidean method
in MeV 4.8 (row and column normalized data) [10,11]. In the linear
relative scale, 1.0 denotes no change in proliferation (100%), and 0.7
denotes 30% reduction in proliferation. Each screening was performed
in three to four biological replicates. Arrows denote miRNAs that were
selected for further validation. B) Integration of miRNA expression data
and primary screening functional data for the A172 glioma cell line
shown in a scatter-plot (log2 mean data on both axes). MiRNA
expression is presented as the ratio of expression in the cell line
compared to the normal brain reference miRNA (log2). Some miRNAs
highlighted with arrows in panel A are marked in panel B.
doi:10.1371/journal.pone.0060930.g001
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Invitrogen protocol by applying the 96-well protocol to the 384-
well format and staining cells with Hoechst 33342 stain. Cells were
visualized using ScanR automated fluorescence microscopy
(Olympus Corp, Tokyo, Japan).
MiRNA Expression Analyses
MiRNA expression was profiled with the Agilent Human
miRNA Microarray Kit (V1) (Agilent Technologies, Santa Clara,
CA, USA). The RNA was isolated from A172, LN405, U87MG,
and SVGp12 cells with the mirVana miRNA Kit (Applied
Biosystems) and labeled according to the Agilent protocol (version
1.0, April 2007). The arrays were scanned with the Agilent
Microarray G2565 Scanner; the scanner was controlled with
Agilent Scan Control software. Default settings recommended by
Agilent were used as the scanning parameters (including the use of
an extended dynamic range with green PMT set to XDR Hi 100%
and XDR Lo 5%). Agilent Feature Extraction Software (version
9.5) was used to extract the data. Human normal brain total RNAs
including miRNAs (Ambion) were used as the reference sample.
The data were normalized using the vsn R-package and
generalized log2 variance stabilization. Each column was cali-
brated by an affine transformation, and then all the data were
transformed with a variance-stabilizing transformation [9] to
remove systematic array biases and make the variances in-
dependent of the mean intensity. The resulting ratios were log2
scale miRNA expression in the cell line compared to normal brain
reference tissue expression.
Figure 2. Validation of hit precursor miRNAs that reduced proliferation with A) CellTiter-Glo assay at 72 h after transfection (n=3
biological, 4 technical repeats), B) monitoring cell growth and confluence by taking time-lapse phase contrast images with an
IncuCytePlus microscope at 95 h after transfection (n=3). Values are mean +/2 s.e.m.; statistically significant changes are shown with
asterisks (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0060930.g002
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Gene Expression Profiling of Gliomas on Oligonucleotide
Microarrays
MiRNA expression was profiled at the genome-wide gene
expression level using the Affymetrix U133 Plus 2.0 GeneChip
(Affymetrix, Santa Clara, CA, USA) according to the manufac-
turer’s instructions. Before hybridization, the yield and quality of
the total RNA were evaluated with the NanoDrop ND-1000 UV-
Vis Spectrophotometer, and the integrity of the RNA provided
was assessed using the Agilent Technologies 2100 Bioanalyzer.
Integration of miRNA Expression and Functional Profiling
Data
To compare the miRNA expression levels to the proliferation
effects caused by pre-miR transfections, we plotted the two sets of
data in one scatter-plot for each cell line (Figure 1B). We used the
twofold difference from the median of all cancer cell lines as
a significant deviation from average miRNA expression. For the
functional screening data, we set the hit cut-off to two standard
deviations from the normalized mean of the screenings.
Figure 3. Validation of the precursor hit miRNAs that reduced proliferation with the Caspase 3/7 Glo assay 72 h after transfection
(n=3 biological, 4 technical repeats). Values are mean +/2 s.e.m.; statistically significant changes are shown with asterisks (*p,0.05, **p,0.01,
***p,0.001).
doi:10.1371/journal.pone.0060930.g003
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Small Interfering RNA Primary and Secondary Screening
SiRNA screening was performed essentially the same way as the
miRNA screening. Briefly, the A172, LN405, U87MG, and
SVGp12 cells were transfected with the 15 nM human Kinase
siRNA library (2241 siRNAs, Ambion Inc.) or human Cancer
siRNA Set (2375 siRNAs, Qiagen GmbH) using Silentfect (Bio-
Rad Laboratories) in a 384-well format. The predetermined
optimal number of cells (1,000–1,500 cells per well) was then
added to the plates, and further incubated for 72 h at 37uC with
5% CO2. Cell viability was measured with CellTiter-Blue or
CellTiter-Glo assays, and induction of caspase-3 and -7 activities
was detected with homogenous ApoOne assay (Promega). The
EnVision Multilabel Plate Reader (PerkinElmer) was used to
quantify the signals. The siRNA screening data were normalized
plate-wise for row and column effects, and the results from the
replicate screenings were combined for the analyses (only part of
the data is shown).
Computational Data Analysis and Statistical Analysis
Hierarchical clustering was performed with the TM4 Multi
Experiment Viewer 4.8 [10,11]. The microRNA target filter of the
Ingenuity Pathways Analysis (IPA; Ingenuity Systems) program
was used to analyze the miRNAs and their predicted targets, and
to integrate the target gene expression in the glioma cell lines.
Student’s t-test was used to calculate the p-values for the
experiments. All p-values are two-sided with the number of
samples (n) shown in the figure text.
TCGA GBM data of 308 patients with clinical information and
9 normal brain tissues were downloaded and analyzed by Anduril
integration tool [12]. Statistical analysis, Student’s T-test and log2-
scale fold change, were done on level 3 microRNA expression data
from TCGA and transcript expression data preprocessed by
Multiple Exon Array Preprocessing (MEAP) algorithm [13] for
candidate microRNAs and their targets. Kaplan-Meier analysis
was performed as described previously in Ovaska et al. [12],
where patients were grouped based on the expression differences
from the median expression of normal tissues (low level: -1 group;
high level: 0 group).
Results
Systematic Functional Screening of microRNAs
To discover the miRNAs that affect cell proliferation, three
glioblastoma cell lines, A172, LN405, and U87MG, and one
control SV40 transformed fetal astroglial cell line, SVGp12, were
screened in a 384-well format for cell proliferation using a human
pre-miR miRNA Precursor library (Ambion) containing 319
miRNA precursor molecules. Cell viability was determined via
adenosine triphosphate (ATP) quantification, as an indication of
metabolically active cells, with the CellTiterBlue luminescence
assay (Promega Corp). Primary proliferation screening data was
normalized plate-wise for row and column effects, and the results
from three to four replicate screenings were combined for the
analyses (Figure 1A). Hits for miRNA precursors that reduce
proliferation were determined as two standard deviations below
the mean of the replicate wells. In total, 24 potential proliferation-
reducing precursor miRNA molecules were found in the primary
screening (Table S1). These miRNAs were selected for secondary
validation screening with proliferation and additional apoptosis
endpoint with the homogenous Caspase-Glo 3/7 Assay (Promega)
(Figure S1). In total, nine miRNAs were validated in the secondary
screening as being repeating proliferation-reducing and/or apo-
ptosis-increasing hits when the cells were transfected with the pre-
miR miRNA precursor molecules (Ambion Inc.) (marked with
arrows in Figure 1A). For further validation, two of the cell lines
(A172 and LN405) were also screened for cell proliferation and
apoptosis induction using a larger precursor library with 819
molecules (Dharmacon, Lafayette, CO, USA). Eight of the nine
previously identified miRNAs (hsa-miR-136, -145, -155, -181b, -
342-5p, -342-3p, -376a/b) were also validated in the Dharmacon
precursor miRNA screenings in the A172 and LN405 cell lines.
One of the nine miRNA precursors, miR-129, had a hit only in
the U87MG cell line, which was not screened with the
Dharmacon precursor library.
Integration of miRNA Expression and Functional Profiling
Data
Each of the four cell lines was profiled for miRNA and mRNA
expression. The data from the functional miRNA precursor
screening were integrated in the miRNA expression profiling data
to find how the nine miRNA precursors are expressed in the
cancer cell lines compared to normal brain reference RNA.
Figure 1B shows the miRNA expression of the A172 glioblastoma
plotted against the precursor miRNA proliferation effects from the
primary screenings. Six miRNAs (miR-181b, -432, -136, -145, -
Figure 4. Kaplan-Meier analysis of the hsa-miR-145 miRNA in
clinical TCGA GBM samples (n=268 in total). Significant survival
difference with p,0.005 is seen between the hsa-miR-145 low
expression group (group denoted with 21, n = 53) who have poor
survival and the high or normal expression group (denoted with 0,
n = 215) with a threefold change threshold between patient groups.
doi:10.1371/journal.pone.0060930.g004
Table 1. Significant differences in miRNA expression of the
functionally relevant miRNAs in clinical GBM tumor samples
(n = 308) compared to normal brain (n = 9) from the TCGA








hsa-miR-136 7.52E-14 21.69 NS
hsa-miR-145 5.88E-04 21.04 0.005
hsa-miR-155 1.18E-21 1.94 NS
hsa-miR-181b 5.44E-02 20.22 NS
hsa-miR-342 4.35E-10 21.25 NS
hsa-miR-129 1.29E-16 23.39 NS
hsa-miR-376a 4.35E-07 20.63 NS
hsa-miR-376b 7.37E-02 0.07 NS
Survival p-value was calculated from miRNA expression data with Kaplan-Meier
analysis. Expression and survival p-values are considered significant if the p-
value is less than p,5.00E–02. NS not significant.
doi:10.1371/journal.pone.0060930.t001
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342, -9) cluster clearly separately based on the stronger effect on
proliferation of the precursor miRNAs and are underexpressed in
the A172 cell line compared to the normal brain (Figure 1B). The
precursor miR-196b and miR-155 show an effect on proliferation
but are overexpressed. The proliferation effects of miR-9, miR-
196b, and miR-432 were not consistent in all cell lines and were
therefore left out from further validation.
Functional Validation of the Selected miRNAs
Nine miRNA precursor molecules (hsa-miR-129, -136, -145, -
155, -181b, -342-5p, -342-3p, -376a/b) were selected for
additional validation experiments based on the functional and
expression data. The nine miRNAs had an antiproliferative effect
in several glioma cancer cell lines, and were less effective in the
control cell line SVGp12. First, the functional effects were
validated using the CellTiter-Glo assay (Figure 2A). Cell pro-
liferation was also monitored by taking time-lapse phase contrast
images with the IncuCytePlus microscope (Essen Instruments) that
automatically quantitated cell confluency (Figure 2B). Introducing
the AllStars Cell Death Control siRNA or KIF11_7 control
siRNAs into the A712, LN405, and U87MG cell lines caused
a significant reduction in cell proliferation as determined via ATP
quantity. Interestingly, overexpression of miRNA precursors hsa-
miR-155, -145, -181b, -136, -129, and -376a/b caused significant
reduction in cell proliferation in the A172 and LN405 cell lines.
Most of these same miRNA precursors were tested and caused
reduction in cell confluency of the A172 and LN405 cell lines,
except miR-145, which had a significant effect in time-lapse phase
contrast microscopy only in the A172 cell line (Figure 2). The
U87MG glioblastoma cell line was less sensitive to the introduction
of the nine miRNAs; only hsa-miR-129, -376a, -376b, and -342-
5p reduced cell proliferation significantly in the CellTiter-Glo
assay, and of these miRNAs, hsa-miR-342-5p significantly reduced
cell confluency. The Caspase-Glo 3/7 assay showed miRNA
precursors that increase apoptosis when overexpressed in glioma
cells (Figure 3). In the A172 cell line, miRNA precursors miR-155,
-145, -181b, -342-5p, and -136 caused a clear increase of 400% to
600% in caspase-3 and -7 activity compared to the scrambled
siRNA transfected cells. Many of the same miRNA precursors also
increased apoptosis in the LN405 cell line, including miR-155, -
181b, -342-5p, and -136. Again, the U87MG cell line was less
sensitive to the nine miRNAs; only miR-155 and -342-5p caused
a significant increase in apoptosis in the U87MG cell line (Figure 3,
lowest panel). Lower sensitivity of the U87MG cell line could be
caused by lower transfection efficiency as KIF11 cell death
controls also showed a smaller effect in the proliferation and
apoptosis assays. The cell cycle was analyzed to understand more
of the cell proliferation effects in addition to apoptosis. The
clearest effects were observed for miR-145, which caused an S
phase block to the cell cycle in the A172 cell line and a similar
effect in the LN405 cell line although this was not significant
(Figure S2). MiR-155 also caused detraction in the cell cycle in the
LN405 and U87MG cell lines; however, this effect was not
consistent and was more cell line specific.
Expression of the Proliferation Reducing miRNAs in
Clinical GBM Samples
Next, we wanted to know how these functionally interesting
miRNAs were expressed in clinical glioblastoma tumor samples.
For eight of the miRNAs (hsa-miR-129,-136, -145, -155, -181b, -
342, -376a/b), expression array data were available from the
Cancer Genome Atlas (TCGA) project data [14-16]. The TCGA
miRNA data with 308 GBM patient samples and nine normal
samples were analyzed with the Anduril data integration tool [12].
Six miRNAs (hsa-miR-136, -145, -155, -376a, -342, and -129) had
significantly different expression values when compared to normal
brain tissue (Table 1). All the other miRNAs were expressed at
lower levels in GBM than in the normal brain except miR-155,
which was expressed almost twofold higher in the GBM samples.
The high expression of miR-155 was also seen in our cell lines.
Low expression of hsa-miR-145 in GBM tumors was significantly
associated with poor survival based on a Kaplan-Meier analysis
(Figure 4). The mean survival time for patients with high or low
levels (high level: 0 group, low level: –1 group) of hsa-miR-145 was
14.9 months and 10.7 months, respectively. Higher hsa-miR-145
expression in GBM tumors yielded significantly longer survival (p-
value,0.005, fold-change threshold = 3, n=53 and n=215 in
groups) in a small subset of patients; the longest survival time was
120 months, whereas in the miR-145 low expression group, the
longest survival time was only 40 months.
Several Putative Targets of the Proliferation Reducing
miRNAs in GBMs
Each miRNA can target hundreds to thousands of different
target genes by silencing them indirectly at the transcriptional and
translational levels. Only a few validated miRNA–target relations
are currently known, and several programs predict target genes for
miRNAs based on the short miRNA seed sequence. Instead of
focusing on a single miRNA target, we wanted to study the
potential target genes more systematically. The miRNAs that
reduced proliferation were analyzed with the IPA program. The
predicted and experimentally proven targets of each miRNA that
Figure 5. Silencing of selected miRNA target genes in four cell lines to validate results from the glioma siRNA screening: functional
assays showing increased apoptosis (ApoOne, Promega) or inhibition of cell proliferation (CellTiter-Glo, Promega) relative to
control wells normalized to zero (negative control siRNA or lipid only). MET, CSF1R, FGF7, and RHOA are previously experimentally observed
mir-155 targets. ROCK1 and EIF2AK1 are highly predicted miRNA targets of mir-145 from Target Scan (see Table 3). Values are mean +/2 s.e.m., loess
normalized log2 data from secondary validation screening (n = 3–4). The p-values are two-sided and are compared to the negative control wells.
Statistically significant changes are shown with asterisks (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0060930.g005
Table 2. Predicted targets of the eight microRNAs (in total












Predicted mRNA targets for 8 miRNAs 6458
doi:10.1371/journal.pone.0060930.t002
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reduced proliferation provided by the IPA program are shown in
Table 2. In total, 6,458 target genes were predicted by the IPA
program for the eight miRNAs that reduced proliferation found in
our study available in IPA, ranging from 448 genes for miR-342-
5p to 2,149 genes for the miR-129 cluster. To filter out the most
relevant miRNA target genes, we combined our existing high-
throughput siRNA screening cell proliferation data (not shown in
their entirety) with the miRNA target predictions and filtered in
genes that cause reduced proliferation or increased apoptosis when
silenced with siRNA transfection in these same cell lines (Table 3).
The 10 genes shown in Table 3 were found to cause either
reduced proliferation or increased apoptosis in glioma cell lines
with two or more siRNAs or in two to three cell lines. Six miRNA
target genes are presented here with a reduced proliferation or
increased apoptosis phenotype in any of the four cell lines
(Figure 5, Table 3). The hsa-miR-155 target genes MET, RHOA,
CSF1R, and FGF7 have been previously experimentally validated
as miR-155 targets in other cell line models [17–21]. Statistically
significant changes are shown for each cell line compared to the
control wells (mean of scrambled siRNAs and lipid-only wells
normalized to zero). The control cell line SVGp12 generally shows
none or smaller proliferation and apoptosis effects with these
siRNA transfections compared to the three glioma cell lines
(Figure 5). This is in line with the miRNA proliferation effects that
were more pronounced with the glioma cell lines than with the
control astrocyte cell line.
The expression of these putative miRNA target genes was also
analyzed in the clinical GBM samples from the TCGA data. Five
of the 10 genes identified in Table 3 (CSF1R, ROCK1, RHOA,
EIF2AK1, and SALL1) were significantly overexpressed in the
GBM data compared to the normal brain in the TCGA cohort
[12] following the logic of underexpressed miRNA and an
overexpressed target gene. FGF7 was not significantly differentially
expressed, and MET, CAMK1D, MARK2, and PRKCE were
significantly underexpressed (Table 4). MiR-155 was overexpessed
and has been experimentally proven to target MET [17,18], and
MET was underexpressed in the GBM TCGA cohort following
the logic of the overexpressed miRNA and underexpressed target
gene. Low MET expression was linked to longer survival (n=225)
in the TCGA data analyzed with Anduril (Figure S3).
Table 3. Predicted miRNA target genes with proliferation-decreasing or apoptosis-inducing phenotype in siRNA screenings of the
glioma cell lines.
miRNA Source Confidence Target gene Entrez Gene Name Hit type
hsa-miR-155 TarBase Experimentally Observed MET met proto-oncogene (hepatocyte growth factor
receptor)
1
hsa-miR-155 miRecords Experimentally Observed RHOA ras homolog gene family, member A 1
hsa-miR-155 Ingenuity Expert Findings,
TargetScan Human
Experimentally Observed CSF1R colony stimulating factor 1 receptor 1
hsa-miR-181b TargetScan Human High (predicted) PRKCE protein kinase C, epsilon 1
hsa-miR-342-5p TargetScan Human Moderate (predicted) MARK2 MAP/microtubule affinity-regulating kinase 2 1
hsa-miR-155 TargetScan Human High (predicted) SALL1 sal-like 1 (Drosophila) 1
hsa-miR-155 Ingenuity Expert Findings,
TargetScan Human,miRecords
Experimentally Observed FGF7 fibroblast growth factor 7 1
hsa-miR-145 TargetScan Human High (predicted) ROCK1 Rho-associated, coiled-coil containing protein
kinase 1
2
hsa-miR-145 TargetScan Human High (predicted) CAMK1D calcium/calmodulin-dependent protein kinase ID 2
hsa-miR-145 TargetScan Human High (predicted) EIF2AK1 eukaryotic translation initiation factor 2-alpha
kinase 1
2
hsa-miR-181b TargetScan Human Moderate (predicted) EIF2AK1
hsa-miR-342-5p TargetScan Human Moderate (predicted) EIF2AK1
Hit type column: 1 = validated with 2 or more siRNAs, 2 = validated in 2–3 cell lines.
doi:10.1371/journal.pone.0060930.t003
Table 4. Significant differences in mRNA expression of the
functionally relevant miRNA target genes in the clinical GBM
tumor samples (n = 308) compared to normal brain (n = 9)
from the TCGA GBM dataset as analyzed with the Anduril tool
[12].








MET 0.388 7.03e-9 0.0964 0.2970.532 0.0368
CSF1R 1.41 0.00528 NA 1.34 2.02 NA
FGF7 0.743 0.392 NA 0.7690.769 NA
ROCK1 1.79 8.57e-5 NA 1.86 1.86 NA
RHOA 1.47 2.43e-5 NA 1.44 1.59 NA
EIF2AK1 1.47 4.67e-5 NA 1.47 1.53 NA
SALL1 2.15 2.58e-8 0.883 2.01 2.39 0.225
CAMK1D 0.176 7.60e-9 NA 0.1400.307 0.00533
MARK2 0.602 7.24e-6 NA NA NA NA
PRKCE 0.165 8.83e-12 NA 0.1620.509 NA
The gene expression measures the expression of the exons linked with the
particular gene in Ensembl. Expression values are considered significant if the p-
value is less than p,5.00E–02. Transcript expressions are calculated from the
exon expression with linear algebra-based method discussed in MEAP [13].
Minimum transcript expression denotes minimum splice variant expression and
maximum transcript expression denotes maximum splice variant expression.
Survival p-values were calculated from the gene expression data with Kaplan-
Meier analysis. NA, Not Available.
doi:10.1371/journal.pone.0060930.t004
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Discussion
Since microRNAs were discovered, there have been several
publications of miRNA expression in various cancers. Generally,
microRNAs are mainly down-regulated in cancers, as is the case
with miR-128, miR-181a, miR-181b, and miR-181c in glioblas-
tomas [7]. Only a few miRNAs, such as miR-221 and miR-21, are
strongly up-regulated in GBM and grade II–IV astrocytic tumors
[8]. In our study, we systematically analyzed the functions of
miRNAs by overexpressing precursor miRNAs in glioma cell lines
and assaying the proliferation and apoptosis phenotypes. The
hypothesis behind our approach was to find miRNAs that would
be down-regulated at the expression level in gliomas and whose
function was tumor suppressor–like when overexpressed in this
cancer type. We found 24 potential precursor miRNA molecules
that reduced proliferation in the primary screening, and nine of
these miRNAs were validated in more detail for their effects on
reducing proliferation or inducing apoptosis. According to the
CellTiter-Glo assay, overexpression of seven miRNA precursors
(hsa-miR-155, -145, -181b, -136, -129, and -376a/b) caused
significant reduction in cell proliferation in the A172 and LN405
cell lines, whereas four miRNA precursors (hsa-miR-129, -376a, -
376b, and -342-5p) significantly reduced cell proliferation in the
U87MG cell line. The lower response rate in the U87MG cell line
to miRNA overexpression could be caused by lower transfection
efficiency. Five of the miRNA precursors (hsa-miR-155, -145, -
181b, -342-5p, and -136) induced apoptosis via caspase-3 and -7
activation. Five miRNAs, hsa-miR-136, -145, -376a, -342, and -
129, showed significantly lower expression values in the GBM
patient tissue samples compared to normal brain tissue.
We found that hsa-miR-181b functions as a tumor suppressor
and overexpression inhibited growth and induced apoptosis.
Similar results have been found previously, as hsa-miR-181a and
especially hsa-miR-181b mature miRNAs have been shown to be
expressed at low levels in GBM and miR-181b in astrocytomas
compared to the normal brain [8,22] as well as function as tumor
suppressors and inhibit invasion of glioma cells [23]. These
findings are in line with our findings for miR-181b. In addition,
low miR-181b expression levels have been found to correlate with
poor survival in patients with astrocytomas compared to patients
with high miR-181b expression levels (p-value,0.039, [22]). This
survival effect for miR-181b was not seen in the TCGA GBM
cohort.
MiR-342-5p is predicted to target EIF2AK1, which we found
was a proliferation-reducing hit when silenced in the GBM cell
lines. Interestingly, EIF2AK1 is a predicted target of three
proliferation-connected miRNAs in this study, and EIF2AK1 acts
at the level of translation initiation to down-regulate protein
synthesis in response to stress [24] and its overexpression can cause
loss of cell proliferation [25]. MiR-342 is an important mediator of
tamoxifen response in breast tumor cell lines and breast cancer
patients; restoring miR-342 expression sensitized breast cancer
cells to tamoxifen-induced apoptosis with a dramatic reduction in
cell growth [26].
Hsa-miR-145 was expressed at significantly lower levels in
GBM patient tissue samples and cell lines when compared to
normal brain tissue, and low expression of miR-145 in GBM
tumors was significantly associated with poor survival based on
a Kaplan-Meier analysis of the TCGA GBM data. Overexpression
of the miR-145 precursor reduced cell proliferation in the A172
and LN405 cell lines and increased apoptosis in the A172 cell line.
Previously, the pluripotency factors OCT4, SOX2, and KLF4 were
shown to be direct targets of miR-145. Increased miR-145
expression inhibits self-renewal, represses expression of pluripo-
tency genes, and induces lineage-restricted differentiation in
human embryonic stem cells [27]. In glioblastoma multiforme,
SOX2 down-regulates miR-145, and both are probably involved in
a double-negative feedback loop in maintaining the stemness of
glioma stem cells [27,28]. The predicted targets of miR-145,
ROCK1 and EIF2AK1, were proliferation-reducing siRNA hits in
our study resembling the miR-145 proliferation effect and thus
proving these experimentally as novel putative miRNA targets.
Expression of ROCK1 and EIF2AK1 was up-regulated in the
clinical GBM TCGA samples conforming to down-regulated miR-
145. Interestingly, Rho/ROCK signaling has been previously
shown to be involved in GBM cell migration and proliferation via
use of ROCK inhibitor Y-27632 or siRNA silencing [29].
Unlike the other underexpressed tumor suppressor miRNAs
found in this study, microRNA-155 is a known oncomir in many
cancers, and is thought to regulate multiple genes associated with
cancer cell proliferation, apoptosis, and invasiveness [30,31].
Elevated miR-155 levels were found in the TCGA GBM data and
in other datasets such as primary and secondary glioblastoma
tissues, glioblastoma primary cultures [32], and the cell lines in our
study. MiR-155 has been previously shown to target many genes,
e.g., MET [17,18], FGF7 [19], RHOA [20], and CSF1R [21] all
whose silencing reduced the GBM cell line proliferation in our
study. As RHOA, CSF1R, and miR-155 were all overexpressed in
clinical GBM samples compared to normal brain tissue, they do
not form a logical reciprocal miRNA - target gene pair, and
therefore also other mechanisms not yet understood must be
involved here. However, MET expression was low in the clinical
GBM samples, and miR-155, which has been shown to target
MET, was overexpressed, thus establishing a logical association
between the overexpressed miRNA and underexpressed target
pair. Low MET expression was linked to longer survival in the
majority of the clinical GBM samples (n=225), and in only a small
number of patients (n=22) was high MET oncogene transcript
expression linked to poor survival. The hypothesis behind our
approach was to find miRNAs that would be down-regulated at
the expression level in gliomas and whose function would be tumor
suppressor–like when overexpressed in this cancer type. We were
successful in discovering nine novel functional miRNAs in the
GBM cell lines and, with the indirect functional siRNA validation
approach showed six putative novel target genes for these
miRNAs. Four of the six target genes, MET, RHOA, CSF1R,
and FGF7, have been previously shown to be direct targets of these
miRNAs, and the two remaining, ROCK1 and EIF2AK1, are
predicted miRNA targets. Thus, although these target genes were
not shown as direct target genes here, we believe that combining
the miRNA and siRNA screening data can provide novel and
more systematic understanding of miRNA biology and cancer
biology in general than focusing on determining a single direct
miRNA target. The TCGA GBM clinical miRNA and gene
expression data confirmed our cell line findings, showing the
relevance of the traditional cell line models recently shown in two
big cell line–based studies [33,34]. Functional miRNA screening
studies will provide vast amounts of information on the unknown
microRNA functions and when integrated with siRNA functional
studies will uncover the general vulnerabilities of cancer cell
pathways.
Supporting Information
Figure S1 Hierarchical clustering of repeated hits from
the miRNA pre-miR functional proliferation secondary
screening using the Euclidean method in MeV 4.8 (Loess
log normalized log2 data) [10,11]. Each screening was
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performed with three to four biological replicates. Arrows denote
miRNAs that were selected for further validation.
(PDF)
Figure S2 Cell cycle analysis after miRNA precursor
overexpression using the Click-it Edu Alexa 647 nm
fluor HCS assay kit (Invitrogen Carlsbad, CA, USA) and
Hoechst 33342 stain for the A172, LN405, and U87MG
cells. Each assay was repeated three times with a 48 h time point
after miRNA transfection. Values are mean +/2 s.e.m.;
statistically significant changes are shown with asterisks (*p-
value,0.05, **p-value,0.01, ***p-value,0.001).
(PDF)
Figure S3 Kaplan-Meier analysis of the MET oncogene
in the clinical GBM samples (n=382 in total). Significant
survival difference with p,0.0368 was seen between the MET low
expression group (group denoted with –1, blue line, n= 225) with
better survival and the high expression group (denoted with 1, red
line, n= 22) with a twofold change threshold between the patient
groups. The normal average expression group is denoted with
a green line (0 group, n= 135).
(PDF)
Table S1 An Excel file of screening data from miRNA pre-miR
libraries in glioma cell lines. Sheet 1) Data from the human pre-
miR miRNA Precursor library v2 (Ambion Inc., 319 molecules)
screening. Data have been normalized for row and column effects.
Sheet 2) Data from the human miRIDIAN microRNA Mimic
Libraries v10.1 (Dharmacon, Lafayette, 819 molecules) screening.
Data are presented as Loess log normalized log2 data.
(XLSX)
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